They’ve been fighting a fearsome opponent. Now shrink it down to size.*

KOSELUGO® (selumetinib) is an FDA-approved treatment for adults and children with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).1 Only Koselugo is approved for the treatment of children as young as 1 year old with NF1 PN.1

*In the KOMET study, 20% of adult patients in the Koselugo group achieved ≥20% PN volume reduction (14/71; 95% CI: 11,31) vs 5% in the placebo group (4/74; 95% CI: 2, 13) from baseline at the end of Cycle 16. DCO August 5, 2024. In SPRINT Phase 2 Stratum 1, 66% of pediatric patients achieved ≥20% PN volume reduction (33/50; 95% CI: 51, 79). DCO June 2018. These responses were confirmed at a subsequent assessment within 3-6 months.1,2

Kylie, age 19, living with NF1 PN.
Kylie is taking Koselugo.

KOSELUGO® (selumetinib) offers a choice

Koselugo can be taken as capsules or oral granules, giving you and your patients a choice in how they take Koselugo.1 Visit our Dosing page for guidance on choosing the right formulation for your patients.

Quentin, age 18, living with NF1 PN, shown with his mom.
Quentin is currently taking Koselugo.